Tab. 6 Sono rappresentati i dati relativi a larghezza (L) e spessore (S), espressi in
mm, dei muscoli retto femorale (RF) e tibiale anteriore (TA) per ciascuna acquisizione di ciascun paziente.
Paziente INGRESSO 7 GIORNI 15 GIORNI 30 GIORNI 45 GIORNI
RF TA RF TA RF TA RF TA RF TA 1 L 36,9 38,7 L 26 27,6 L L 27 29 L S 10,2 11,2 S 8,8 9,5 S S 8 9 S 2 L 24 22,3 L L 22 25 L L 19 26 S 4,9 13 S S 7 7,8 S S 4 8,1 3 L 32,3 33,7 L 30 34,3 L L L S 12,4 13,2 S 11 8,4 S S S 4 L 34 33,6 L L L L S 22,1 17,6 S S S S 5 L 24,2 27 L 23 25,3 L L L S 5 7,8 S 5,7 9 S S S 6 L 21,7 29 L 20 30,1 L L L S 7,1 13,9 S 6,3 10,2 S S S 7 L 29,9 26,6 L 31 24,6 L 25 25 L 31 24 L S 8,9 14,2 S 9,3 11,6 S 10 12 S 8 14 S 8 L 33,1 21,5 L 33 22 L 26 22 L L S 10,2 12,3 S 9,1 11,8 S 7 10 S S 9 L L 32 31,1 L L L S S 9,4 10,5 S S S 10 L 31,6 30,4 L 25 30,8 L L 22 31 L S 6,5 20,9 S 6,8 18,5 S S 6 17 S 11 L 17,4 23,9 L 21 18,1 L L 24 23 L 25 26 S 6,7 11 S 4,7 12,5 S S 5 9 S 7 13 12 L 30,7 32,8 L 33 32,9 L 31 25 L L S 8,3 13,7 S 9,9 13,1 S 10 11 S S 13 L L 21 29,4 L 23 29 L 19 29 L S S 9,9 20,2 S 10 12 S 7 12 S 14 L 31,3 31,4 L 30 27,6 L L L S 9,6 11,4 S 10 12,2 S S S 15 L L 27 20 L 26 24 L L S S 6,6 12,1 S 6 15 S S 16 L L 31 32,1 L 32 38 L L S S 9,1 12,9 S 8 24 S S 17 L 33,8 30,2 L 29 26,4 L L L S 6,3 13,4 S 7,5 13,2 S S S
Tab. 7 Valori dell’area (A) della sezione trasversa dei muscoli retto femorale (RF) e
tibiale anteriore(TA).
N Ingresso 7 giorni 15 giorni 30 giorni 45 giorni
RF TA RF TA RF TA RF TA RF TA 1 A 32788 29372 22876 24000 27015 19823 2 A 14160 16787 14676 19433 13238 17976 3 A 17567 17364 16971 18137 4 A 17074 14366 5 A 10998 13322 9823 11564 6 A 15157 15070 15234 14791 7 A 32209 22130 34110 22022 23978 19258 20287 17028 8 A 27461 20537 29368 19767 22008 19886 9 A 20006 27401 10 A 23734 18940 19825 19021 16876 18180 11 A 15893 22574 14944 19558 15185 18357 16668 15584 12 A 18576 24251 20014 15790 20362 15092 13 A 20047 16228 16468 16060 20056 12118 14 A 30757 25279 28742 26314 15 A 21715 18842 12507 16604 16 A 17222 14425 15883 12155 17 A 19814 18828 20237 16431
Tab. 8 Sono riportati i dati ecografici riguardanti la media della scala di grigi, e la
sua deviazione standard, e la media granulare per ciascuna acquisizione di tutti i pazienti.
N Ingresso 7 giorni 15 giorni 30 giorni 45 giorni
RF TA RF TA RF TA RF TA RF TA 1 M 56,89 65,32 36,97 50,8 50,3 74,14 DS 36,44 32,34 35,83 41,8 42,3 37,14 GM 3,22 4,86 2,93 4,02 3,65 5,56 2 M 112,85 79,29 76 75 90,57 51,5 DS 50,58 42,38 43 36 49,3 39,4 GM 5,32 5,07 5 4,9 5,52 4,82 3 M 71,35 39,56 62,47 34,3 DS 38,56 30,06 35,12 31 GM 5,36 3,42 4,81 3,62 4 M 63,27 38,41 DS 41,12 35,83 GM 5,39 3,37 5 M 75,43 75,81 88,21 79,1 DS 32,24 37,62 28,99 40,2 GM 4,72 5,41 6,03 6,17 6 M 119,83 98,76 121,03 106 DS 52,65 31,12 41,68 32,7 GM 6,54 4,53 6,16 5,96 7 M 42,176 81,27 37,32 71,4 46 61 30,61 54,22 DS 36,13 37,23 36,27 39,8 36 36 32,8 38,72 GM 3,27 4,51 3,12 4,91 4,1 4,4 2,86 4,14 8 M 75,42 86,12 67,14 77 120 112 DS 51,48 46,27 46,91 51,7 54 53 GM 5,02 5,37 4,61 4,86 4,6 5,4 9 M 62,24 95 DS 48,42 43,3 GM 4,58 4,91
N
Ingresso 7 giorni 15 giorni 30 giorni 45 giorni
RF TA RF TA RF TA RF TA RF TA 10 M 92,65 82,05 87,48 70,6 75,9 67,57 DS 42,37 33,16 41,05 34,6 38,2 33,51 GM 5,28 4,74 5,12 4,81 4,76 4,53 11 M 79,95 69,94 73,68 45 84,1 65,99 100,9 67,6 DS 44,77 35,67 45,73 33,4 38,2 48,91 40,15 43,7 GM 5,06 5,26 5,41 4,41 5,75 5,04 6,34 5,97 12 M 61,93 48,12 33,82 37,8 29 43 DS 53,59 33,13 40,91 30,5 36 29 GM 4,18 3,57 2,89 3,14 3,1 4 13 M 92,53 107 76 61 53 63,52 DS 46,18 38,2 43 40 39,7 31,68 GM 4,59 5,31 4,7 4,5 3,78 4,49 14 M 62,64 67,98 64,71 53,5 DS 44,22 36,91 38,96 32,7 GM 4,21 5,25 4,13 4,79 15 M 50,68 51 52 50 DS 42,34 29,6 46 33 GM 3,61 4,29 5,1 6,2 16 M 105,4 91,6 96 84 DS 58,56 49,1 43 41 GM 6,78 6,46 7,2 7,5 17 M 39,11 98,44 42,57 83,5 DS 33,52 61,14 30,12 57,3 GM 3,79 6,07 3,06 5,84
BIBLIOGRAFIA
1. Vincent JL, Norrenberg M. Intensive care unit-acquired weakness: framing the topic. Crit Care Med. 2009;37(10 Suppl):S296-8.
2. Gutmann L, Gutmann L. Critical illness neuropathy and myopathy. Arch Neurol. 1999;56(5):527-8.
3. Latronico N, Rasulo FA. Presentation and management of ICU myopathy and neuropathy. Curr Opin Crit Care. 2010;16(2):123-7.
4. Young GB. Intensive care unit/critical illness myopathy: toward a unifying hypothesis? Crit Care Med. 2007;35(2):628-9.
5. Judemann K, Lunz D, Zausig YA, Graf BM, Zink W. [Intensive care unit-acquired weakness in the critically ill : critical illness polyneuropathy and critical illness myopathy]. Anaesthesist. 2011;60(10):887-901.
6. Garcia de Lorenzo A, Vilas E, Rodriguez Montes JA. [Pathophysiology of neuromuscular impairments in the critically ill patient]. Nutr Hosp. 2006;21 Suppl 3:96-103.
7. Dos Santos CC, Batt J. ICU-acquired weakness: mechanisms of disability. Curr Opin Crit Care. 2012;18(5):509-17.
8. de Jonghe B, Lacherade JC, Sharshar T, Outin H. Intensive care unit-acquired weakness: risk factors and prevention. Crit Care Med. 2009;37(10 Suppl):S309-15. 9. Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Clinical review: Critical
illness polyneuropathy and myopathy. Critical care. 2008;12(6):238.
10. Denehy L, Elliott D. Strategies for post ICU rehabilitation. Curr Opin Crit Care. 2012;18(5):503-8.
11. Lee CM, Fan E. ICU-acquired weakness: what is preventing its rehabilitation in critically ill patients? BMC Med. 2012;10:115.
12. Desai SV, Law TJ, Needham DM. Long-term complications of critical care. Critical care medicine. 2011;39(2):371-9.
13. Griffiths RD, Hall JB. Intensive care unit-acquired weakness. Crit Care Med. 2010;38(3):779-87.
14. Hough CL, Needham DM. The role of future longitudinal studies in ICU survivors: understanding determinants and pathophysiology of weakness and neuromuscular dysfunction. Curr Opin Crit Care. 2007;13(5):489-96.
15. Deem S. Intensive-care-unit-acquired muscle weakness. Respir Care. 2006;51(9):1042-52; discussion 52-3.
16. Confer J, Wolcott J, Hayes R. Critical illness polyneuromyopathy. Am J Health Syst Pharm. 2012;69(14):1199-205.
17. Latronico N, Candiani A. Neuromuscular abnormalities in patients with organ failure and sepsis. Intensive care medicine. 1994;20(8):612-3.
18. Bloch S, Polkey MI, Griffiths M, Kemp P. Molecular mechanisms of intensive care unit-acquired weakness. Eur Respir J. 2012;39(4):1000-11.
19. Dowdy DW, Eid MP, Sedrakyan A, Mendez-Tellez PA, Pronovost PJ, Herridge MS, et al. Quality of life in adult survivors of critical illness: a systematic review of the literature. Intensive care medicine. 2005;31(5):611-20.
20. Latronico N, Shehu I, Seghelini E. Neuromuscular sequelae of critical illness. Current opinion in critical care. 2005;11(4):381-90.
21. Callahan LA, Supinski GS. Sepsis-induced myopathy. Critical care medicine. 2009;37(10 Suppl):S354-67.
22. Hermans G, Agten A, Testelmans D, Decramer M, Gayan-Ramirez G. Increased duration of mechanical ventilation is associated with decreased diaphragmatic force: a prospective observational study. Crit Care. 2010;14(4):R127.
23. Schweickert WD, Hall J. ICU-acquired weakness. Chest. 2007;131(5):1541-9.
24. Ali NA, O'Brien JM, Jr., Hoffmann SP, Phillips G, Garland A, Finley JC, et al. Acquired weakness, handgrip strength, and mortality in critically ill patients. Am J Respir Crit Care Med. 2008;178(3):261-8.
25. Mirzakhani H, Williams JN, Mello J, Joseph S, Meyer MJ, Waak K, et al. Muscle weakness predicts pharyngeal dysfunction and symptomatic aspiration in long-term ventilated patients. Anesthesiology. 2013;119(2):389-97.
26. Paratz J, Thomas P, Adsett J. Re-admission to intensive care: identification of risk factors. Physiother Res Int. 2005;10(3):154-63.
27. Fan E. Critical illness neuromyopathy and the role of physical therapy and rehabilitation in critically ill patients. Respir Care. 2012;57(6):933-44; discussion 44- 6.
28. Azoulay E, Kentish-Barnes N, Pochard F. Health-related quality of life: an outcome variable in critical care survivors. Chest. 2008;133(2):339-41.
29. Hermans G, Van Mechelen H, Clerckx B, Vanhullebusch T, Mesotten D, Wilmer A, et al. Acute Outcomes and 1-Year Mortality of Intensive Care Unit-acquired Weakness. A Cohort Study and Propensity-matched Analysis. American journal of respiratory and critical care medicine. 2014;190(4):410-20.
30. Bailey PP, Miller RR, 3rd, Clemmer TP. Culture of early mobility in mechanically ventilated patients. Crit Care Med. 2009;37(10 Suppl):S429-35.
31. Hopkins RO, Miller RR, 3rd, Rodriguez L, Spuhler V, Thomsen GE. Physical therapy on the wards after early physical activity and mobility in the intensive care unit. Phys Ther. 2012;92(12):1518-23.
32. Kress JP, Herridge MS. Medical and economic implications of physical disability of survivorship. Semin Respir Crit Care Med. 2012;33(4):339-47.
33. Hermans G, Wilmer A, Meersseman W, Milants I, Wouters PJ, Bobbaers H, et al. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. American journal of respiratory and critical care medicine. 2007;175(5):480-9.
34. Needham DM, Dowdy DW, Mendez-Tellez PA, Herridge MS, Pronovost PJ. Studying outcomes of intensive care unit survivors: measuring exposures and outcomes. Intensive care medicine. 2005;31(9):1153-60.
35. Batt J, dos Santos CC, Cameron JI, Herridge MS. Intensive care unit-acquired weakness: clinical phenotypes and molecular mechanisms. Am J Respir Crit Care Med. 2013;187(3):238-46.
36. Kasotakis G, Schmidt U, Perry D, Grosse-Sundrup M, Benjamin J, Ryan C, et al. The surgical intensive care unit optimal mobility score predicts mortality and length of stay. Critical care medicine. 2012;40(4):1122-8.
37. Argov Z, Latronico N. Neuromuscular complications in intensive care patients. Handbook of clinical neurology. 2014;121:1673-85.
38. Herridge MS, Batt J, Santos CD. ICU-acquired Weakness, Morbidity, and Death. American journal of respiratory and critical care medicine. 2014;190(4):360-2. 39. Fan E, Dowdy DW, Colantuoni E, Mendez-Tellez PA, Sevransky JE, Shanholtz C, et al.
Physical complications in acute lung injury survivors: a two-year longitudinal prospective study. Crit Care Med. 2014;42(4):849-59.
40. Lemiale V, Kentish-Barnes N, Chaize M, Aboab J, Adrie C, Annane D, et al. Health- related quality of life in family members of intensive care unit patients. Journal of palliative medicine. 2010;13(9):1131-7.
41. Lipshutz AK, Gropper MA. Acquired neuromuscular weakness and early mobilization in the intensive care unit. Anesthesiology. 2013;118(1):202-15.
42. Brummel NE, Jackson JC, Girard TD, Pandharipande PP, Schiro E, Work B, et al. A combined early cognitive and physical rehabilitation program for people who are critically ill: the activity and cognitive therapy in the intensive care unit (ACT-ICU) trial. Phys Ther. 2012;92(12):1580-92.
43. Hocker SE, Wijdicks EF. Neurologic complications of sepsis. Continuum (Minneap Minn). 2014;20(3 Neurology of Systemic Disease):598-613.
44. Kentish-Barnes N, Lemiale V, Chaize M, Pochard F, Azoulay E. Assessing burden in families of critical care patients. Critical care medicine. 2009;37(10 Suppl):S448-56. 45. Rukstele CD, Gagnon MM. Making strides in preventing ICU-acquired weakness:
involving family in early progressive mobility. Crit Care Nurs Q. 2013;36(1):141-7. 46. Stevens RD, Hart N, de Jonghe B, Sharshar T. Weakness in the ICU: a call to action.
Crit Care. 2009;13(6):1002.
47. Ponfick M, Bosl K, Ludemann-Podubecka J, Neumann G, Pohl M, Nowak DA, et al. [Intensive care unit acquired weakness. Pathogenesis, treatment, rehabilitation and outcome]. Nervenarzt. 2014;85(2):195-204.
48. Schefold JC, Bierbrauer J, Weber-Carstens S. Intensive care unit-acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shock. J Cachexia Sarcopenia Muscle. 2010;1(2):147-57.
49. Bierbrauer J, Koch S, Olbricht C, Hamati J, Lodka D, Schneider J, et al. Early type II fiber atrophy in intensive care unit patients with nonexcitable muscle membrane. Crit Care Med. 2012;40(2):647-50.
50. Derde S, Hermans G, Derese I, Guiza F, Hedstrom Y, Wouters PJ, et al. Muscle atrophy and preferential loss of myosin in prolonged critically ill patients. Crit Care Med. 2012;40(1):79-89.
51. Stibler H, Edstrom L, Ahlbeck K, Remahl S, Ansved T. Electrophoretic determination of the myosin/actin ratio in the diagnosis of critical illness myopathy. Intensive Care Med. 2003;29(9):1515-27.
52. Wollersheim T, Woehlecke J, Krebs M, Hamati J, Lodka D, Luther-Schroeder A, et al. Dynamics of myosin degradation in intensive care unit-acquired weakness during severe critical illness. Intensive Care Med. 2014;40(4):528-38.
53. Batt J, Dos Santos CC, Herridge MS. Muscle injury during critical illness. JAMA : the journal of the American Medical Association. 2013;310(15):1569-70.
54. Callahan LA, Supinski GS. Sepsis induces diaphragm electron transport chain dysfunction and protein depletion. American journal of respiratory and critical care medicine. 2005;172(7):861-8.
55. Nelson WB, Smuder AJ, Hudson MB, Talbert EE, Powers SK. Cross-talk between the calpain and caspase-3 proteolytic systems in the diaphragm during prolonged mechanical ventilation. Critical care medicine. 2012;40(6):1857-63.
56. Supinski GS, Wang W, Callahan LA. Caspase and calpain activation both contribute to sepsis-induced diaphragmatic weakness. Journal of applied physiology. 2009;107(5):1389-96.
57. Jackson MJ, McArdle A. Age-related changes in skeletal muscle reactive oxygen species generation and adaptive responses to reactive oxygen species. The Journal of physiology. 2011;589(Pt 9):2139-45.
58. Rennie MJ. Anabolic resistance in critically ill patients. Critical care medicine. 2009;37(10 Suppl):S398-9.
59. Aare S, Radell P, Eriksson LI, Chen YW, Hoffman EP, Larsson L. Role of sepsis in the development of limb muscle weakness in a porcine intensive care unit model. Physiol Genomics. 2012;44(18):865-77.
60. Hermans G, Vanhorebeek I, Derde S, Van den Berghe G. Metabolic aspects of critical illness polyneuromyopathy. Critical care medicine. 2009;37(10 Suppl):S391-7. 61. O'Neill ED, Wilding JP, Kahn CR, Van Remmen H, McArdle A, Jackson MJ, et al.
Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation. Age. 2010;32(2):209-22.
62. Jackson MJ. Control of reactive oxygen species production in contracting skeletal muscle. Antioxidants & redox signaling. 2011;15(9):2477-86.
63. Latronico N. Monitoring of peripheral nerves and muscle function in patients with multiple organ dysfunction syndrome. Critical care medicine. 2000;28(9):3375. 64. Winkelman C. The role of inflammation in ICU-acquired weakness. Crit Care.
2010;14(4):186.
65. Bertolini G, Latronico N, Brazzi L, Radrizzani D. Insulin dose or glycemic control for the critically ill? Critical care medicine. 2003;31(10):2565-6; author reply 6.
66. Jackson MJ. Skeletal muscle aging: role of reactive oxygen species. Critical care medicine. 2009;37(10 Suppl):S368-71.
67. Powers SK, Ji LL, Kavazis AN, Jackson MJ. Reactive oxygen species: impact on skeletal muscle. Comprehensive Physiology. 2011;1(2):941-69.
68. Callahan LA, Stofan DA, Szweda LI, Nethery DE, Supinski GS. Free radicals alter maximal diaphragmatic mitochondrial oxygen consumption in endotoxin-induced sepsis. Free radical biology & medicine. 2001;30(1):129-38.
69. Puthucheary Z, Harridge S, Hart N. Skeletal muscle dysfunction in critical care: wasting, weakness, and rehabilitation strategies. Crit Care Med. 2010;38(10 Suppl):S676-82.
70. Chambers MA, Moylan JS, Reid MB. Physical inactivity and muscle weakness in the critically ill. Crit Care Med. 2009;37(10 Suppl):S337-46.
71. Hall JB, Schweickert W, Kress JP. Role of analgesics, sedatives, neuromuscular blockers, and delirium. Crit Care Med. 2009;37(10 Suppl):S416-21.
72. Daniell H. Drug-induced cortisol deficiency as a cause of intensive care unit weakness. Crit Care Med. 2010;38(4):1231-2; author reply 2.
73. Maramattom BV, Wijdicks EF. Acute neuromuscular weakness in the intensive care unit. Crit Care Med. 2006;34(11):2835-41.
74. Stevens RD, Marshall SA, Cornblath DR, Hoke A, Needham DM, de Jonghe B, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med. 2009;37(10 Suppl):S299-308.
75. Meherali SM, Parpio Y, Ali TS. Critical illness myopathy. J Pak Med Assoc. 2010;60(11):961-3.
76. Khan J, Burnham EL, Moss M. Acquired weakness in the ICU: critical illness myopathy and polyneuropathy. Minerva anestesiologica. 2006;72(6):401-6.
77. Anzueto A. Muscle dysfunction in the intensive care unit. Clin Chest Med. 1999;20(2):435-52.
78. Raghig H, Young GB, Hammond R, Nicolle M. A comparison of EMG and muscle biopsy in ICU weakness. Neurocrit Care. 2010;13(3):326-30.
79. Lacomis D, Petrella JT, Giuliani MJ. Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. Muscle Nerve. 1998;21(5):610-7. 80. Hermans G, Casaer MP, Clerckx B, Guiza F, Vanhullebusch T, Derde S, et al. Effect of
tolerating macronutrient deficit on the development of intensive-care unit acquired weakness: a subanalysis of the EPaNIC trial. Lancet Respir Med. 2013;1(8):621-9. 81. Aare S, Radell P, Eriksson LI, Akkad H, Chen YW, Hoffman EP, et al. Effects of
corticosteroids in the development of limb muscle weakness in a porcine intensive care unit model. Physiol Genomics. 2013;45(8):312-20.
82. Hund E. Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol. 2001;248(11):929-34.
83. Bolton CF, Young GB. Managing the nervous system effects of sepsis. Chest. 2007;131(5):1273-4.
84. Needham DM. Mobilizing patients in the intensive care unit: improving neuromuscular weakness and physical function. JAMA. 2008;300(14):1685-90. 85. Howard RS, Tan SV, Z'Graggen WJ. Weakness on the intensive care unit. Pract
Neurol. 2008;8(5):280-95.
86. Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. The Cochrane database of systematic reviews. 2009(1):CD006832.
87. Bittner EA, Martyn JA, George E, Frontera WR, Eikermann M. Measurement of muscle strength in the intensive care unit. Critical care medicine. 2009;37(10 Suppl):S321-30.
88. Hermans G, Clerckx B, Vanhullebusch T, Segers J, Vanpee G, Robbeets C, et al. Interobserver agreement of Medical Research Council sum-score and handgrip strength in the intensive care unit. Muscle & nerve. 2012;45(1):18-25.
89. Bittner EA, Martyn JA, George E, Frontera WR, Eikermann M. Measurement of muscle strength in the intensive care unit. Crit Care Med. 2009;37(10 Suppl):S321- 30.
90. Hough CL, Lieu BK, Caldwell ES. Manual muscle strength testing of critically ill patients: feasibility and interobserver agreement. Crit Care. 2011;15(1):R43.
91. Vanpee G, Hermans G, Segers J, Gosselink R. Assessment of limb muscle strength in critically ill patients: a systematic review. Crit Care Med. 2014;42(3):701-11.
92. Vanpee G, Segers J, Van Mechelen H, Wouters P, Van den Berghe G, Hermans G, et al. The interobserver agreement of handheld dynamometry for muscle strength assessment in critically ill patients. Crit Care Med. 2011;39(8):1929-34.
93. Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute skeletal muscle wasting in critical illness. JAMA : the journal of the American Medical Association. 2013;310(15):1591-600.
94. Hermans G, Gosselink R. Should we abandon manual muscle strength testing in the ICU? Crit Care. 2011;15(2):127.
95. Baldwin CE, Paratz JD, Bersten AD. Muscle strength assessment in critically ill patients with handheld dynamometry: an investigation of reliability, minimal detectable change, and time to peak force generation. J Crit Care. 2013;28(1):77-86. 96. Kho ME, Truong AD, Brower RG, Palmer JB, Fan E, Zanni JM, et al. Neuromuscular
electrical stimulation for intensive care unit-acquired weakness: protocol and methodological implications for a randomized, sham-controlled, phase II trial. Phys Ther. 2012;92(12):1564-79.
97. Kane SL, Dasta JF. Clinical outcomes of critical illness polyneuropathy. Pharmacotherapy. 2002;22(3):373-9.
98. Nordon-Craft A, Schenkman M, Ridgeway K, Benson A, Moss M. Physical therapy management and patient outcomes following ICU-acquired weakness: a case series. J Neurol Phys Ther. 2011;35(3):133-40.
99. Ochala J, Renaud G, Llano Diez M, Banduseela VC, Aare S, Ahlbeck K, et al. Diaphragm muscle weakness in an experimental porcine intensive care unit model. PLoS One. 2011;6(6):e20558.
100. Lefaucheur JP, Nordine T, Rodriguez P, Brochard L. Origin of ICU acquired paresis determined by direct muscle stimulation. J Neurol Neurosurg Psychiatry. 2006;77(4):500-6.
101. Argov Z, Latronico N. Neuromuscular complications in intensive care patients. Handb Clin Neurol. 2014;121:1673-85.
102. Latronico N, Shehu I, Guarneri B. Use of electrophysiologic testing. Crit Care Med. 2009;37(10 Suppl):S316-20.
103. Lacomis D. Electrodiagnostic approach to the patient with suspected myopathy. Neurologic clinics. 2012;30(2):641-60.
104. Morris PE, Herridge MS. Early intensive care unit mobility: future directions. Critical care clinics. 2007;23(1):97-110.
105. Cartwright MS, Kwayisi G, Griffin LP, Sarwal A, Walker FO, Harris JM, et al. Quantitative neuromuscular ultrasound in the intensive care unit. Muscle Nerve. 2013;47(2):255-9.
106. Wieske L, Witteveen E, Petzold A, Verhamme C, Schultz MJ, van Schaik IN, et al. Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot study. Crit Care. 2014;18(2):R18.
107. Weitzel LR, Sandoval PA, Mayles WJ, Wischmeyer PE. Performance-enhancing sports supplements: role in critical care. Crit Care Med. 2009;37(10 Suppl):S400-9. 108. Rennie MJ. Anabolic resistance: the effects of aging, sexual dimorphism, and
immobilization on human muscle protein turnover. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. 2009;34(3):377- 81.
109. Ruiz-Santana S, Arboleda Sanchez JA, Abiles J. [Guidelines for specialized nutritional and metabolic support in the critically-ill patient. Update. Consensus of the Spanish Society of Intensive Care Medicine and Coronary Units-Spanish Society of Parenteral and Enteral Nutrition (SEMICYUC-SENPE): nutritional assessment]. Med Intensiva. 2011;35 Suppl 1:12-6.
110. Erbas O, Ergenoglu AM, Akdemir A, Yeniel AO, Taskiran D. Comparison of melatonin and oxytocin in the prevention of critical illness polyneuropathy in rats with experimentally induced sepsis. J Surg Res. 2013;183(1):313-20.
111. Farivar BS, Eiref SD, Leitman IM. Strategies to prevent sepsis-induced intensive care unit-acquired weakness: are there any options? Commentary on "Comparison of melatonin and oxytocin in the prevention of critical illness polyneuropathy in rats with surgically induced sepsis". J Surg Res. 2013;185(1):e39-42.
112. Truong AD, Fan E, Brower RG, Needham DM. Bench-to-bedside review: mobilizing patients in the intensive care unit--from pathophysiology to clinical trials. Crit Care. 2009;13(4):216.
113. Kress JP. Clinical trials of early mobilization of critically ill patients. Crit Care Med. 2009;37(10 Suppl):S442-7.
114. Garzon-Serrano J, Ryan C, Waak K, Hirschberg R, Tully S, Bittner EA, et al. Early mobilization in critically ill patients: patients' mobilization level depends on health care provider's profession. PM & R : the journal of injury, function, and rehabilitation. 2011;3(4):307-13.
115. Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. The Cochrane database of systematic reviews. 2014;1:CD006832.
116. Misak CJ. ICU-acquired weakness: obstacles and interventions for rehabilitation. Am J Respir Crit Care Med. 2011;183(7):845-6.
117. Nydahl P, Ruhl AP, Bartoszek G, Dubb R, Filipovic S, Flohr HJ, et al. Early mobilization of mechanically ventilated patients: a 1-day point-prevalence study in Germany. Critical care medicine. 2014;42(5):1178-86.
118. Rodriguez PO, Setten M, Maskin LP, Bonelli I, Vidomlansky SR, Attie S, et al. Muscle weakness in septic patients requiring mechanical ventilation: protective effect of transcutaneous neuromuscular electrical stimulation. J Crit Care. 2012;27(3):319 e1- 8.
119. Proceedings of a Round Table Conference in Brussels, Belgium, March 2009, October 2009. Crit Care Med. 2009;37(10 Suppl):S295-461.
120. Nordon-Craft A, Moss M, Quan D, Schenkman M. Intensive care unit-acquired weakness: implications for physical therapist management. Phys Ther. 2012;92(12):1494-506.
121. Puthucheary Z, Hart N. Intensive care unit acquired muscle weakness: when should we consider rehabilitation? Crit Care. 2009;13(4):167.
122. Gehlbach BK, Kress JP. Sedation in the intensive care unit. Current opinion in critical care. 2002;8(4):290-8.
123. Kress JP. Sedation and mobility: changing the paradigm. Crit Care Clin. 2013;29(1):67-75.
124. Piriyapatsom A, Bittner EA, Hines J, Schmidt UH. Sedation and paralysis. Respiratory care. 2013;58(6):1024-37.
125. Kress JP, Pohlman AS, Hall JB. Sedation and analgesia in the intensive care unit. American journal of respiratory and critical care medicine. 2002;166(8):1024-8. 126. Needham DM, Truong AD, Fan E. Technology to enhance physical rehabilitation of
critically ill patients. Crit Care Med. 2009;37(10 Suppl):S436-41.
127. Trees DW, Smith JM, Hockert S. Innovative mobility strategies for the patient with intensive care unit-acquired weakness: a case report. Phys Ther. 2013;93(2):237-47. 128. Parry SM, Berney S, Granger CL, Koopman R, El-Ansary D, Denehy L. Electrical
muscle stimulation in the intensive care setting: a systematic review. Crit Care Med. 2013;41(10):2406-18.
129. Angelopoulos E, Karatzanos E, Dimopoulos S, Mitsiou G, Stefanou C, Patsaki I, et al. Acute microcirculatory effects of medium frequency versus high frequency neuromuscular electrical stimulation in critically ill patients - a pilot study. Ann Intensive Care. 2013;3(1):39.
130. Kho ME, Truong AD, Brower RG, Palmer JB, Fan E, Zanni JM, et al. Neuromuscular electrical stimulation for intensive care unit-acquired weakness: protocol and methodological implications for a randomized, sham-controlled, phase II trial. Physical therapy. 2012;92(12):1564-79.
131. Zanotti E, Felicetti G, Maini M, Fracchia C. Peripheral muscle strength training in bed-bound patients with COPD receiving mechanical ventilation: effect of electrical stimulation. Chest. 2003;124(1):292-6.
132. Bailey PP, Miller RR, 3rd, Clemmer TP. Culture of early mobility in mechanically ventilated patients. Critical care medicine. 2009;37(10 Suppl):S429-35.
133. Callahan LA, Supinski GS. Prevention and treatment of ICU-acquired weakness: is there a stimulating answer? Critical care medicine. 2013;41(10):2457-8.
134. Korupolu R, Zanni JM, Fan E, Butler M, Needham DM. Early mobilisation of intensive care unit patient: the challenges of morbid obesity and multiorgan failure. BMJ case reports. 2010;2010.
135. Heckmatt J, Rodillo E, Doherty M, Willson K, Leeman S. Quantitative sonography of muscle. Journal of child neurology. 1989;4 Suppl:S101-6.
136. Heckmatt JZ, Dubowitz V. Diagnostic advantage of needle muscle biopsy and ultrasound imaging in the detection of focal pathology in a girl with limb girdle dystrophy. Muscle Nerve. 1985;8(8):705-9.
137. Heckmatt JZ, Leeman S, Dubowitz V. Ultrasound imaging in the diagnosis of muscle disease. The Journal of pediatrics. 1982;101(5):656-60.
138. Heckmatt JZ, Pier N, Dubowitz V. Measurement of quadriceps muscle thickness and subcutaneous tissue thickness in normal children by real-time ultrasound imaging. Journal of clinical ultrasound : JCU. 1988;16(3):171-6.
139. Grimm A, Teschner U, Porzelius C, Ludewig K, Zielske J, Witte OW, et al. Muscle ultrasound for early assessment of critical illness neuromyopathy in severe sepsis. Crit Care. 2013;17(5):R227.
140. Heckmatt JZ, Pier N, Dubowitz V. Real-time ultrasound imaging of muscles. Muscle Nerve. 1988;11(1):56-65.
141. Walker FO. Imaging nerve and muscle with ultrasound. Supplements to Clinical neurophysiology. 2004;57:243-54.
142. Cartwright MS, Demar S, Griffin LP, Balakrishnan N, Harris JM, Walker FO. Validity and reliability of nerve and muscle ultrasound. Muscle Nerve. 2013;47(4):515-21. 143. Walker FO, Cartwright MS, Wiesler ER, Caress J. Ultrasound of nerve and muscle.
Clinical neurophysiology : official journal of the International Federation of Clinical